Steinfels G F, Alberici G P, Tam S W, Cook L
E.I. du Pont de Nemours & Co., Inc., Medical Products Department, Wilmington, Delaware 19898.
Neuropsychopharmacology. 1988 Dec;1(4):321-7.
Research on the sigma receptor, a binding site associated with drug-induced psychotomimetic behaviors, has been hampered because most sigma agonists also interact with the phencyclidine (PCP) receptor. (+)-Pentazocine, a human psychotogen, is a selective sigma receptor ligand. To demonstrate sigma receptor activities, we studied the behavioral and electrophysiologic actions for (+)-pentazocine. In the behavioral drug discrimination procedure in which rats were trained to discriminate between 2.0 mg/kg (5.59 mumol/kg) (+)-pentazocine and saline, (+)-pentazocine produced dose-related increases in the percentage of trials completed on the (+)-pentazocine lever. At a dose of 1.0 mg/kg (3.29 mumol/kg) (+)-N-allylnormetazocine generalized completely to (+)-pentazocine. By contrast, PCP only partially generalized. In the visual evoked potential test, these compounds produced a significant dose-dependent slowing of the N2 latency. This response was prevented by haloperidol pretreatment. These results demonstrate pharmacologic actions for the selective sigma receptor ligand (+)-pentazocine and suggest some overlapping pharmacologic properties of the sigma and PCP receptor sites despite differences in central nervous system distribution.
对西格玛受体(一种与药物诱发的拟精神病行为相关的结合位点)的研究受到了阻碍,因为大多数西格玛激动剂也与苯环己哌啶(PCP)受体相互作用。(+)-喷他佐辛是一种人类致幻剂,是一种选择性西格玛受体配体。为了证明西格玛受体的活性,我们研究了(+)-喷他佐辛的行为和电生理作用。在行为药物辨别程序中,大鼠被训练区分2.0毫克/千克(5.59微摩尔/千克)的(+)-喷他佐辛和生理盐水,(+)-喷他佐辛使在(+)-喷他佐辛杠杆上完成的试验百分比产生剂量相关的增加。在1.0毫克/千克(3.29微摩尔/千克)的剂量下,(+)-N-烯丙基去甲美沙酮完全能替代(+)-喷他佐辛。相比之下,PCP只能部分替代。在视觉诱发电位测试中,这些化合物使N2潜伏期出现显著的剂量依赖性延长。这种反应可被氟哌啶醇预处理所阻断。这些结果证明了选择性西格玛受体配体(+)-喷他佐辛的药理作用,并表明尽管西格玛和PCP受体位点在中枢神经系统分布上存在差异,但它们具有一些重叠的药理特性。